Dow Turns Lower; Amazon Shares Jump After Strong Q2 Results
Portfolio Pulse from Lisa Levin
US stocks pared gains with the Dow Jones and S&P 500 turning lower. Amazon shares rose by 10% after reporting strong Q2 results, beating consensus estimates. Missfresh, US Cellular, and Telephone and Data Systems also saw significant gains. However, Mesoblast, Assertio Holdings, and INVO Bioscience shares dropped significantly. The US economy added 187,000 jobs in July, slightly below market estimates.
August 04, 2023 | 6:30 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Amazon shares rose by 10% after reporting strong Q2 results, beating consensus estimates.
Amazon's strong Q2 results and positive future revenue expectations have led to a significant increase in its share price.
CONFIDENCE 100
IMPORTANCE 100
RELEVANCE 100
POSITIVE IMPACT
Missfresh shares shot up 281% after the company announced entry of share purchase agreements for financing and business acquisition.
Missfresh's announcement of share purchase agreements for financing and business acquisition has led to a significant increase in its share price.
CONFIDENCE 100
IMPORTANCE 100
RELEVANCE 100
POSITIVE IMPACT
Telephone and Data Systems shares were up, gaining 82% after the company announced the exploration of strategic alternatives for US Cellular and reported second-quarter financial results.
Telephone and Data Systems' announcement of the exploration of strategic alternatives for US Cellular and positive Q2 results have led to a significant increase in its share price.
CONFIDENCE 100
IMPORTANCE 100
RELEVANCE 100
POSITIVE IMPACT
Shares of United States Cellular Corporation got a boost, shooting 91% following quarterly results.
US Cellular's positive quarterly results have led to a significant increase in its share price.
CONFIDENCE 100
IMPORTANCE 100
RELEVANCE 100
NEGATIVE IMPACT
Shares of Assertio Holdings were down 45% after the company reported second-quarter financial results and withdrew its 2023 financial outlook.
Assertio Holdings' negative Q2 results and withdrawal of its 2023 financial outlook have led to a significant decrease in its share price.
CONFIDENCE 100
IMPORTANCE 100
RELEVANCE 100
NEGATIVE IMPACT
INVO Bioscience was down, falling 39% after the company announced pricing of $4.5 million public offering of 1.58 million units at a price of $2.85 per unit.
INVO Bioscience's announcement of the pricing of its public offering has led to a significant decrease in its share price.
CONFIDENCE 100
IMPORTANCE 100
RELEVANCE 100
NEGATIVE IMPACT
Mesoblast shares dropped 61% after the FDA issued a complete response letter to Mesoblast’s resubmission for remestemcel-L for pediatric steroid-refractory acute graft versus host disease.
The FDA's complete response letter to Mesoblast’s resubmission for remestemcel-L has led to a significant decrease in its share price.
CONFIDENCE 100
IMPORTANCE 100
RELEVANCE 100